Evidence map›Paper›PMID 18199654›Full record

ArticleJournal of virology2008

Targets of small interfering RNA restriction during human immunodeficiency virus type 1 replication.

Yong Gao, Michael A Lobritz, Justin Roth, Measho Abreha, Kenneth N Nelson, Immaculate Nankya, Dawn M Moore-Dudley, Awet Abraha, Stanton L Gerson, Eric J Arts

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. CRISPR-Cas13a Inhibits HIV-1 Infection.Molecular therapy. Nucleic acids · 2020
    Article
  3. Article
  4. Review
  5. Ribonucleic acid interference induced gene knockdown.Journal of Indian Society of Periodontology · 2013
    Review
  6. Article
  7. Article
  8. Toward a durable anti-HIV gene therapy based on RNA interference.Annals of the New York Academy of Sciences · 2009
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yong GaoDivision of Infectious Diseases, BRB 1034, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH 44106, USA.
Michael A Lobritz
Justin Roth
Measho Abreha
Kenneth N Nelson
Immaculate Nankya
Dawn M Moore-Dudley
Awet Abraha
Stanton L Gerson
Eric J Arts
Office of Infectious Diseases · USCase Western Reserve University · US

Funding

WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Sharon L. Hillier, JONATHAN KARN · 1994 to 2026
$50.0M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4M
Impact of HIV-1 Fitness on Disease ProgressionR01AI049170 · NIAID · UNIVERSITY OF WESTERN ONTARIO · PI ARTS, ERIC J · 2002 to 2024
$6.8M
ANTIGENIC PROPERTIES OF THE V1/V2 DOMAIN OF HIV-1 GP120R01AI046283 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI PINTER, ABRAHAM · 2000 to 2010
$5.1M
Antigenic properties of the V1/V2 domain of HIV-1 gp120R56AI046283 · NIAID · PUBLIC HEALTH RESEARCH INSTITUTE · PI PINTER, ABRAHAM · 2005 to 2005
$493k
HIV-1 Fitness and RecombinationR56AI049170 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ARTS, ERIC J · 2012 to 2012
$400k
Impact of HIV-1 Fitness on Disease ProgressionR21AI049170 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ARTS, ERIC J · 2001 to 2001
$265k
ANTIGENIC PROPERTIES OF THE V1/V2 DOMAIN OF HIV-1 GP120R21AI046283 · NIAID · PUBLIC HEALTH RESEARCH INSTITUTE · PI PINTER, ABRAHAM · 2000 to 2000
$111k
NIAID NIH HHS AI36219NIAID NIH HHS AI436402NIAID NIH HHS AI46283NIAID NIH HHS AI49170NIAID NIH HHS P30 AI036219NIAID NIH HHS R01 AI046283NIAID NIH HHS R01 AI049170NIAID NIH HHS R21 AI046283NIAID NIH HHS R21 AI049170NIAID NIH HHS R56 AI046283NIAID NIH HHS R56 AI049170NIGMS NIH HHS T32 GM007250
6 · The paper itself

Abstract

Small interfering RNAs (siRNAs) have been shown to effectively inhibit human immunodeficiency virus type 1 (HIV-1) replication in vitro. The mechanism(s) for this inhibition is poorly understood, as siRNAs may interact with multiple HIV-1 RNA species during different steps of the retroviral life cycle. To define susceptible HIV-1 RNA species, siRNAs were first designed to specifically inhibit two divergent primary HIV-1 isolates via env and gag gene targets. A self-inactivating lentiviral vector harboring these target sequences confirmed that siRNA cannot degrade incoming genomic RNA. Disruption of the incoming core structure by rhesus macaque TRIM5alpha did, however, provide siRNA-RNA-induced silencing complex access to HIV-1 genomic RNA and promoted degradation. In the absence of accelerated core disruption, only newly transcribed HIV-1 mRNA in the cytoplasm is sensitive to siRNA degradation. Inhibitors of HIV-1 mRNA nuclear export, such as leptomycin B and camptothecin, blocked siRNA restriction. All HIV-1 RNA regions and transcripts found 5' of the target sequence, including multiply spliced HIV-1 RNA, were degraded by unidirectional 3'-to-5' siRNA amplification and spreading. In contrast, HIV-1 RNA 3' of the target sequence was not susceptible to siRNA. Even in the presence of siRNA, full-length HIV-1 RNA is still encapsidated into newly assembled viruses. These findings suggest that siRNA can target only a relatively "naked" cytoplasmic HIV-1 RNA despite the involvement of viral RNA at nearly every step in the retroviral life cycle. Protection of HIV-1 RNA within the core following virus entry, during encapsidation/virus assembly, or within the nucleus may reflect virus evolution in response to siRNA, TRIM5alpha, or other host restriction factors.

Indexed as

Virus ReplicationBase SequenceBlotting, WesternCells, CulturedDNA PrimersDNA, ViralHIV-1HIV Long Terminal RepeatHumansReverse Transcriptase Polymerase Chain ReactionRNA, Small InterferingRNA, ViralTranscription, GeneticDNA PrimersDNA, ViralRNA, Small InterferingRNA, Viral

Identifiers

PMID18199654
PMCPMC2259002
OpenAlexW2133541971

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.